Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a
total that is expected to rise to about 400 million over the next 15–20 years. Most asthmatic …

Context Asthma is readily diagnosed in most cases and usually responds to inhaled
corticosteroids with or without long-acting β agonists, theophyllines, or leukotriene-receptor …

Asthma is a common heterogeneous disease with a complex pathophysiology. Current
therapies based on inhaled corticosteroids and longacting β 2 agonists are effective in …

Drugs available for asthma treatment in the first decades of the 20th century
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …

There has been a recent increase in the prevalence of asthma worldwide; however, the 5–
10% of patients with severe disease account for a substantial proportion of the health costs …

What is becoming clear in filling the pipeline with new asthma therapies that treat the
underlying disease causes is the need for closer working between clinical academics and …

Asthma is an inflammatory disorder in which the small airways of the lung play an important
role. There is also evidence for the systemic nature of asthma. No current method …

Asthma is a disease of reversible airflow obstruction characterised clinically by wheezing,
shortness of breath, and coughing. Increases in airway type 2 cytokine activity, including …

Until 2023, guidelines focused on asthma control as the primary goal of asthma treatment, 1
with the step-wise addition of drugs until the best possible disease control was achieved …

Guidelines for asthma management focus on the use of combination inhaled treatment with
corticosteroids and longacting β-agonists for symptomatic asthma. In more severe disease …